Development and optimization of oral nanoemulsion of rutin for enhancing its dissolution rate, permeability, and oral bioavailability

被引:7
|
作者
Alshahrani, Saad M. [1 ]
机构
[1] Prince Sattam Bin Abdulaziz Univ, Coll Pharm, Dept Pharmaceut, Al Kharj 11942, Saudi Arabia
关键词
Rutin; nanoemulsion; bioavailability; dissolution; permeability; DRUG-DELIVERY SYSTEM; PRE/POST-COMPRESSION PROPERTIES; SOLID CARRIERS; IN-VITRO; IMPACT; NANOSUSPENSION; GLIMEPIRIDE; FORMULATION; QUERCETIN; CHITOSAN;
D O I
10.1080/10837450.2022.2090957
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Rutin-loaded nanoemulsion (NE-RU) formulation is the core research work in this report. Labrafil((R)) M 1944 CS was used as the oil phase, Tween 80 as the surfactant, and Transcutol P as the co-surfactant in the preparation of nanoemulsion. By utilizing a three-level central composite design (CCD), the composition was optimized. The optimized formulation showed a droplet size of 98.53 +/- 3.22 nm, zeta potential -46.70 +/- 4.78 mV, and drug loading 92.34 +/- 3.87%. The results of dissolution, permeability, and oral bioavailability showed about 25.55 folds, 1.98 folds, and 33.68 folds, respectively, in the case of NE-RU as compared to its naive form. The response of fresh and aged NE was non-significantly different in terms of particle size, zeta potential, and drug loading, indicating that the formulation was stable. The successful development of NE-RU with an improved bioavailability profile suggested that this formulation might be used to examine the pharmacodynamics of oxidative stress-related metabolic disorders.
引用
收藏
页码:588 / 597
页数:10
相关论文
共 50 条
  • [42] Development of surface stabilized candesartan cilexetil nanocrystals with enhanced dissolution rate, permeation rate across CaCo-2, and oral bioavailability
    Sanyog Jain
    Venkata Appa Reddy
    Sumit Arora
    Kamlesh Patel
    Drug Delivery and Translational Research, 2016, 6 : 498 - 510
  • [43] Development of surface stabilized candesartan cilexetil nanocrystals with enhanced dissolution rate, permeation rate across CaCo-2, and oral bioavailability
    Jain, Sanyog
    Reddy, Venkata Appa
    Arora, Sumit
    Patel, Kamlesh
    DRUG DELIVERY AND TRANSLATIONAL RESEARCH, 2016, 6 (05) : 498 - 510
  • [44] Enhancing Curcumin Oral Bioavailability Through Nanoformulations
    Vinod S. Ipar
    Anisha Dsouza
    Padma V. Devarajan
    European Journal of Drug Metabolism and Pharmacokinetics, 2019, 44 : 459 - 480
  • [45] Enhancing Curcumin Oral Bioavailability Through Nanoformulations
    Ipar, Vinod S.
    Dsouza, Anisha
    Devarajan, Padma V.
    EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS, 2019, 44 (04) : 459 - 480
  • [46] Approaches for enhancing oral bioavailability of peptides and proteins
    Renukuntla, Jwala
    Vadlapudi, Aswani Dutt
    Patel, Ashaben
    Boddu, Sai H. S.
    Mitra, Ashim K.
    INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2013, 447 (1-2) : 75 - 93
  • [47] Oral linalool-based nanoemulsion of acalabrutinib for ameliorating its oral bioavailability and in vitro anticancer potential in T lymphoblast cell lines
    Shettiwar, Arti
    Gupta, Ujala
    Chatterjee, Essha
    Patra, Bhagyashree
    Aalhate, Mayur
    Mahajan, Srushti
    Maji, Indrani
    Mehra, Neelesh Kumar
    Guru, Santosh Kumar
    Singh, Pankaj Kumar
    COLLOID AND POLYMER SCIENCE, 2024, 302 (10) : 1491 - 1511
  • [48] Potential of Lipid Nanoparticles (SLNs and NLCs) in Enhancing Oral Bioavailability of Drugs with Poor Intestinal Permeability
    Sushama Talegaonkar
    Arundhati Bhattacharyya
    AAPS PharmSciTech, 20
  • [49] Potential of Lipid Nanoparticles (SLNs and NLCs) in Enhancing Oral Bioavailability of Drugs with Poor Intestinal Permeability
    Talegaonkar, Sushama
    Bhattacharyya, Arundhati
    AAPS PHARMSCITECH, 2019, 20 (03)
  • [50] Development of Abiraterone Acetate Nanocrystal Tablets to Enhance Oral Bioavailability: Formulation Optimization, Characterization, In Vitro Dissolution and Pharmacokinetic Evaluation
    Liu, Yuanfen
    Li, Yuqi
    Xu, Pengcheng
    Shen, Yan
    Tang, Baoqiang
    Wang, Qiyue
    PHARMACEUTICS, 2022, 14 (06)